The goal of this project is to elucidate the function of huntingtin protein, mutation of which underlies Huntingtin's disease (HD). These mutations are expansions of a polyglutamine repeat motif (coded by CAG trinucleotide repeats in the mRNA) within the protein, making HD one of several known """"""""glutamine repeat disorders"""""""". In this group of neurodegenerative diseases, an expansion of a polyglutamine repeat in a number of different proteins confers the various disease phenotypes. Transcriptional dysregulation and abnormalities in energy metabolism have been implicated in the pathogenesis of HD. Here we hypothesize that these two processes may be functionally linked in HD. Our preliminary data demonstrates that mutant huntingtin inhibits transcription of coactivator PGC-1a, a major regulator of mitochondrial biogenesis and cellular respiration in several cell types. Increased PGC-1a levels in different tissues lead to enhanced mitochondrial electron transport that enable cells to meet raising energy demands. In this work, we propose to analyze the transcriptional mechanisms by which mutant huntingtin interferes with the function of PGC-1a. Transgenic mice expressing PGC-1a in the brain will be generated and crossed with HD mice to determine whether gain-of-function of PGC-1a alters survival and neuropathology in HD transgenic mice. In addition, mechanisms that lead to modulation of PGC-1a activity in HD will be studied. Upstream regulators controlling PGC-1a transcription in HD cells will be identified to determine whether activation of PGC-1a leads to correction of energy deficits in HD. Target genes of PGC-1a and markers of mitochondrial function will be analyzed in HD cell and tissues. Completion of these aims should reveal new insights into general mechanisms of polyglutamine-induced neurodegeneration and lead to identification of new molecular targets for therapies in HD. ?

Public Health Relevance

The goal of this project is to elucidate neuroprotective mechanisms in Huntington's disease (HD). We have evidence that disruptions of energy metabolism and deregulation of gene transcription are functionally linked in HD. Our preliminary data suggest that mutant huntingtin represses transcriptional regulation of peroxisome proliferator activator receptor coactivator 1 alpha (PGC-1a). Recent studies have implicated PGC-1a as a major regulator of mitochondrial biogenesis and cellular respiration in several cell types, suggesting that disruption of PGC-1a expression may lead to cellular dysfunction and cell death. We propose a study to search for activators and modulators of PGC-1a expression and activity in HD. Since PGC-1alpha has been implicated in various disorders, including Parkinson's disease, such regulators of PGC-1a function may prove valuable for development of neuroprotective therapies for HD and other neurodegenerative disorders. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS051303-01A2
Application #
7472029
Study Section
Special Emphasis Panel (ZRG1-MDCN-M (02))
Program Officer
Sutherland, Margaret L
Project Start
2008-06-01
Project End
2012-02-28
Budget Start
2008-06-01
Budget End
2009-02-28
Support Year
1
Fiscal Year
2008
Total Cost
$351,333
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Kumar, K R; Ramirez, A; Göbel, A et al. (2013) Glucocerebrosidase mutations in a Serbian Parkinson's disease population. Eur J Neurol 20:402-5
Jeong, Hyunkyung; Cohen, Dena E; Cui, Libin et al. (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18:159-65
Usenovic, Marija; Knight, Adam L; Ray, Arpita et al. (2012) Identification of novel ATP13A2 interactors and their role in ?-synuclein misfolding and toxicity. Hum Mol Genet 21:3785-94
Usenovic, Marija; Tresse, Emilie; Mazzulli, Joseph R et al. (2012) Deficiency of ATP13A2 leads to lysosomal dysfunction, ?-synuclein accumulation, and neurotoxicity. J Neurosci 32:4240-6
Jiang, Mali; Wang, Jiawei; Fu, Jinrong et al. (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 18:153-8
Xiang, Zhongmin; Valenza, Marta; Cui, Libin et al. (2011) Peroxisome-proliferator-activated receptor gamma coactivator 1 ? contributes to dysmyelination in experimental models of Huntington's disease. J Neurosci 31:9544-53
Seibler, Philip; Graziotto, John; Jeong, Hyun et al. (2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 31:5970-6
Cao, Kan; Graziotto, John J; Blair, Cecilia D et al. (2011) Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med 3:89ra58
Sadagurski, Marianna; Cheng, Zhiyong; Rozzo, Aldo et al. (2011) IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 121:4070-81
Mazzulli, Joseph R; Xu, You-Hai; Sun, Ying et al. (2011) Gaucher disease glucocerebrosidase and ?-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37-52

Showing the most recent 10 out of 12 publications